New agolorithm predicts gestational diabetes16 min read
With advancing technology, you can view website and know about everything. Now, a new computer algorithm can predict in the early stages of pregnancy, or even before pregnancy has occurred, which women are at a high risk of gestational diabetes – according to a study by researchers at the Weizmann Institute of Science reported today in Nature Medicine. The study analyzed data on nearly 600,000 pregnancies available from Israel’s largest health organization, Clalit Health Services. Based on these predictions, it may be possible to prevent gestational diabetes using nutritional and lifestyle changes.
“Our ultimate goal has been to help the health system take measures so as to prevent diabetes from occurring in pregnancy,” says senior author Prof. Eran Segal of the Computer Science and Applied Mathematics and the Molecular Cell Biology Departments.
Gestational diabetes is characterized by high blood sugar levels that develop during pregnancy in women who did not previously have diabetes. It occurs in 3 to 9 percent of all pregnancies and is fraught with risks for both mother and baby. Typically, gestational diabetes is diagnosed between the 24th and 28th weeks of pregnancy, with the help of a glucose tolerance test in which the woman drinks a glucose solution and then undergoes a blood test to see how quickly the glucose is cleared from her blood.
In the new study, Segal and colleagues started out by applying a machine learning method to Clalit’s health records on some 450,000 pregnancies in women who gave birth between 2010 and 2017. Gestational diabetes had been diagnosed by glucose tolerance testing in about 4 percent of these pregnancies. After processing big data – an enormous dataset made up of more than 2,000 parameters for each pregnancy, including the woman’s blood test results and her and her family’s medical histories – the scientists’ algorithm revealed that nine of the parameters were sufficient to accurately identify the women who were at a high risk of developing gestational diabetes. The nine parameters included the woman’s age, body mass index, family history of diabetes and results of her glucose tests during previous pregnancies (if any).
Next, to make sure that the nine parameters could indeed accurately predict the risk of gestational diabetes, the researchers applied them to Clalit’s health records on about 140,000 additional pregnancies that had not been part of the initial analysis. The results validated the study’s findings: The nine parameters helped to accurately identify the women who ultimately developed gestational diabetes.
These findings suggest that by having a woman answer just nine questions, it should be possible to tell in advance whether she is at a high risk of developing gestational diabetes. And if this information is available early on – in the early stages of pregnancy or even before the woman has gotten pregnant – it might be possible to reduce her risk of diabetes through lifestyle measures such as exercise and diet. On the other hand, women identified by the questionnaire as being at a low risk of gestational diabetes may be spared the cost and inconvenience of the glucose testing.
In more general terms, this study has demonstrated the usefulness of large human-based datasets, specifically electronic health records, for deriving personalized disease predictions that can lead to preventive and therapeutic measures.
The work was led by graduate students Nitzan Shalom Artzi, Dr. Smadar Shilo and Hagai Rossman from Eran Segal’s lab at the Weizmann Institute of Science, who collaborated with Prof. Eran Hadar, Dr. Shiri Barbash-Hazan, Prof. Avi Ben-Haroush and Prof. Arnon Wiznitzer of the Rabin Medical Center in Petah Tikva; and Prof. Ran D. Balicer and Dr. Becca Feldman of Clalit Health Services.
Prof. Eran Segal is head of the Crown Human Genome Center at the Weizmann Institute of Science. His research is supported by the Larson Charitable Foundation New Scientist Fund; the Else Kroener Fresenius Foundation; the Adelis Foundation; Ms. Judith Benattar; Ms. Aliza Moussaieff; the Fannie Sherr Fund; the estate of Zvia Zeroni and the European Research Council.
The Weizmann Institute of Science in Rehovot, Israel, is one of the world’s top-ranking multidisciplinary research institutions. Noted for its wide-ranging exploration of the natural and exact sciences, the Institute is home to scientists, students, technicians and supporting staff. Institute research efforts include the search for new ways of fighting disease and hunger, examining leading questions in mathematics and computer science, probing the physics of matter and the universe, creating novel materials and developing new strategies for protecting the environment.